CD274 and neoplasm: FTO inhibition by the small molecule Dac51 removes metabolic barriers in T cells and blocks tumour immune evasion through glycolytic reprogramming; moreover, Dac51 treatment is synergistic with anti-PD-L1 therapy [108].